Novartis Partners with Virtual Biotech for Diabetes Tech

Apr 19, 2017

Novartis has struck a deal with Parvus Therapeutics -- a small, virtual biotech in Canada -- for exclusive rights to use Parvus' technology to develop and commercialize products for the treatment of type 1 diabetes.

Parvus has entered into a license and collaboration agreement with Novartis for its lead Navacim platform. According to Parvus, Navacims constitute a novel pharmacological class of therapeutic comprised of nanoparticles (NPs) coated with disease-relevant peptide-major histocompatibility complexes (pMHCs) that alter the behavior of disease-causing T lymphocytes.

Novartis will be will be responsible for clinical-stage development and commercialization activities. Parvus will be primarily responsible for conducting the ongoing preclinical work for the T1D program and filing the IND in collaboration with Novartis through a joint steering committee.

Read the press release

Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.


No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments